A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

NCT05816252 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

356

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: SKB264
DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Osimertinib

Sponsor

Klus Pharma Inc.

Collaborators

[object Object]